TY - JOUR
T1 - Metabolism of fatty acids in left ventricle myocardium and the efficacy prognosis of cardio-resynchronizing therapy in dilated cardiomyopathy patients
AU - Gulya, Marina Olegovna
AU - Lishmanov, Yu B.
AU - Zavadovsky, Konstantin Valerievich
AU - Lebedev, D. I.
PY - 2014/1/1
Y1 - 2014/1/1
N2 - Aim. To study perfusion and metabolism of LV myocardium in patients with dilated cardiomyopathy (DCMP) and to invent on this basement a gamma-specific predictors for cardio-resynchronizing therapy (RT) efficacy. Material and methods. Totally 63 patients with DCMP included (41 male, 22 female) with mean age 55,4±8,3 y. o., having congestive heart failure (CHF) of III–IV NYHA. Before RT all patients underwent scintigraphy of myocardium with 99mÈ (for perfusion assessment) and 123I (for fatty acids metabolism). Before and in 6 months after RT all patients underwent echocardiography to assess intracardiac hemodynamics. Results. In 6 months after RT all patients were divided into two groups: 1) EDV LV decreased by ≥15% (n= 39) — “responders”, and 2) ESV LV decreased <15% (n=24) — “non-responders”. Before RT groups did not significantly differ by pumping function of the ventricle. Significant difference was found by following pre-operational scintigraphic parameters: perfusion defect (PD) (9,22±5,06% and 12,5±4,22%, p<0,01), metabolism defect on earlier pictures (MD) (9,21±5,42% and 11,27±5,39%, p<0,01). The equation of multiple regression was invented, which may prognose the dynamics of end-systolic volume after RT. By the ROC analysis data the main prognostic significance for RT has the size of metabolism defect area and calculated value of end-systolic volume dynamics. The best threshold MD=7,35% and it confirms the efficacy of RT with 77,8% sensitivity and 66,7% specificity. The best threshold value of calculated endsystolic volume dynamics — 34,02 confirms the 87,5% sensitivity and 100% specificity of RT. Conclusion. The data collected during metabolic myocardial gamma-scintigraphy may be used in the complex of methods that allow to predict the efficacy of cardioresynchronizing therapy.
AB - Aim. To study perfusion and metabolism of LV myocardium in patients with dilated cardiomyopathy (DCMP) and to invent on this basement a gamma-specific predictors for cardio-resynchronizing therapy (RT) efficacy. Material and methods. Totally 63 patients with DCMP included (41 male, 22 female) with mean age 55,4±8,3 y. o., having congestive heart failure (CHF) of III–IV NYHA. Before RT all patients underwent scintigraphy of myocardium with 99mÈ (for perfusion assessment) and 123I (for fatty acids metabolism). Before and in 6 months after RT all patients underwent echocardiography to assess intracardiac hemodynamics. Results. In 6 months after RT all patients were divided into two groups: 1) EDV LV decreased by ≥15% (n= 39) — “responders”, and 2) ESV LV decreased <15% (n=24) — “non-responders”. Before RT groups did not significantly differ by pumping function of the ventricle. Significant difference was found by following pre-operational scintigraphic parameters: perfusion defect (PD) (9,22±5,06% and 12,5±4,22%, p<0,01), metabolism defect on earlier pictures (MD) (9,21±5,42% and 11,27±5,39%, p<0,01). The equation of multiple regression was invented, which may prognose the dynamics of end-systolic volume after RT. By the ROC analysis data the main prognostic significance for RT has the size of metabolism defect area and calculated value of end-systolic volume dynamics. The best threshold MD=7,35% and it confirms the efficacy of RT with 77,8% sensitivity and 66,7% specificity. The best threshold value of calculated endsystolic volume dynamics — 34,02 confirms the 87,5% sensitivity and 100% specificity of RT. Conclusion. The data collected during metabolic myocardial gamma-scintigraphy may be used in the complex of methods that allow to predict the efficacy of cardioresynchronizing therapy.
KW - Cardioresynchronizing therapy
KW - Dilated cardiomyopathy
KW - Scintigraphy of myocardium
UR - http://www.scopus.com/inward/record.url?scp=84933074045&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84933074045&partnerID=8YFLogxK
U2 - 10.15829/1560-4071-2014-9-61-67
DO - 10.15829/1560-4071-2014-9-61-67
M3 - Article
AN - SCOPUS:84933074045
VL - 113
SP - 61
EP - 67
JO - Russian Journal of Cardiology
JF - Russian Journal of Cardiology
SN - 1560-4071
IS - 9
ER -